pharmaceuticals rivals purchases convinced worldwide shares trading acquisitions branded germany rose said generics able hits offered partially sales merge affiliate however euros sandoz hexal also patent trail copy compensate identical create month research drugs figures expires francs initially pressure overtake pay deal cheaply consolidation us novartis newly kuhlhoff fragmented biggest sell cuts chemically year cost market investment based expensive making world firm buy forecast eon force price remaining adding necessary products drugmakers departments maker would usually oppenheim told make find company producer see teva analysts swiss call last strange work predicted statement job bought producers bn development drugmaker drug strong exactly suffered sal estimated birgit may labs israel protection growth number expected unit record reductions acquired acquisition announced bank reuters outlook savings business jobs merged early generic following markets